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Abstract
Intra-articular injection of mesenchymal stem cells (MSCs) in an osteoarthritic joint can help slow down cartilage destruction.
However, cell survival and the efficiency of repair are generally low due to mechanical damage during injection and a high rate of
cell loss. We, thus, investigated an improved strategy for cell delivery to an osteoarthritic joint through the use of three-
dimensional (3D) microcryogels. MSCs were seeded into 3D microcryogels. The viability and proliferation of MSCs in micro-
cryogels were determined over 5 d, and the phenotype of MSCs was confirmed through trilineage differentiation tests and flow
cytometry. In Sprague Dawley rats with induced osteoarthritis (OA) of the knee joint, a single injection was made with the
following groups: saline control, low-dose free MSCs (1  105 cells), high-dose free MSCs (1  106 cells), and microcryogels þ
MSCs (1 105 cells). Cartilage degeneration was evaluated by macroscopic examination, micro-computed tomographic analysis,
and histology. MSCs grown in microcryogels exhibited optimal viability and proliferation at 3 d with stable maintenance of
phenotype in vitro. Microcryogels seeded with MSCs were, therefore, primed for 3 d before being used for in vivo experiments. At
4 and 8 wk, the microcryogels þ MSCs and high-dose free MSC groups had significantly higher International Cartilage Repair
Society macroscopic scores, histological evidence of more proteoglycan deposition and less cartilage loss accompanied by a
lower Mankin score, and minimal radiographic evidence of osteoarthritic changes in the joint compared to the other two groups.
In conclusion, intra-articular injection of cell-laden 3D microcryogels containing a low dose of MSCs can achieve similar effects as
a high dose of free MSCs for OA in a rat model. Primed MSCs in 3D microcryogels can be considered as an improved delivery
strategy for cell therapy in treating OA that minimizes cell dose while retaining therapeutic efficacy.
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Introduction
Osteoarthritis (OA) is the most prevalent chronic degenera-
tive joint disease and is associated with a serious health
burden both for individuals and society1. The incidence and
prevalence of OA are constantly increasing due to the
world’s aging population2. OA is characterized by cartilage
damage, subchondral bone sclerosis, and osteophyte forma-
tion, resulting in chronic pain and reduced mobility that
severely impact an individual’s quality of life3. Current
treatments for OA include nonpharmacological, pharmaco-
logical, and surgical approaches, all of which can only
provide a transient relief of symptoms4,5. No effective
disease-modifying therapies targeting complicated chronic
joint pathology have been developed for OA6.
Mesenchymal stem cells (MSCs) have been tested over
the last decade as a potential regenerative therapy for treat-
ing OA7. Preclinical and clinical studies have recently
demonstrated some favorable effects on cartilage repair
when MSCs were injected into OA joints in animal models8
and in humans9. The standard method of MSC administra-
tion for treating OA is by direct intra-articular injection of
cells into the affected joint, and any resulting effects are
thought to be due to the anti-inflammatory and pro-
regenerative paracrine functions of the MSCs within the
lesion site10,11. However, the long-term therapeutic benefits
of MSC injections remain limited, and the treatment effects
are sometimes irreproducible due to extensive cell death or
cell loss from the lesion site following injection12. We pre-
viously investigated the effects of injecting human umbilical
cord-derived MSCs (hUC-MSCs) in a rat model of knee OA,
and reported that a single injection could have temporary
effects on slowing cartilage degeneration in the short term13.
Several factors may contribute to the poor effects of cell
therapy administered through direct injection, including
mechanical damage to cells during injection, low rate of cell
retention at the injection site due to leakage to surrounding
tissues, and extensive cell death following injection due to
lack of protection from the extracellular matrix (ECM)14. A
simple and commonly used solution to enhance the efficacy
and reproducibility of MSC therapy for treating OA is to
inject a large dose of cells, which theoretically accounts for
significant cell loss and ensures that a sufficient number of
functional MSCs will remain in the intra-articular space fol-
lowing injection15. However, using high doses of MSCs not
only reduces the practicality of cell therapy due to substan-
tially increasing the costs for cell processing, but also brings
additional risks associated with overexpansion of cells16.
These risks may include uncontrollable cell growth or aber-
rant mutations, particularly when genetically modified
MSCs are used17. There is hence a significant need for
improved delivery strategies to enable low-dose cell therapy,
which can simultaneously minimize the side effects and
enhance the efficacy and reproducibility of treatment.
A number of biomaterial-assisted cell delivery
approaches have been developed to improve MSC injections
for OA18,19. For example, MSCs can be encapsulated in an
aqueous suspension that forms a hydrogel following injec-
tion into an OA joint19. However, while delivery in a hydro-
gel can improve cell retention and survival, the hydrogel
does not promote ECM accumulation and cell–cell interac-
tions for the encapsulated cells. An optimal delivery method
should provide protection to cells during injection, while
providing a suitable environment for the cells to construct
a native cellular niche following injection. We previously
developed injectable three-dimensional (3D) microcryogels
as improved cell delivery vehicles, which were microscopic
porous gelatin hydrogels14,20,21. These microcryogels were
biocompatible and biodegradable, and shown to promote cell
retention and survival following injection in a range of ani-
mal models.
In this study, we hypothesized that using our 3D micro-
cryogels as a delivery vehicle would enhance the survival,
retention, and function of MSCs in treating OA, such that
therapeutic effects could be achieved using a reduced cell
dose. hUC-MSCs were “primed” by preculturing in 3D
microcryogels for 3 d before the cell-laden microcryogels
were injected into the knee joint of rats with induced OA.
Although the microcryogels contained a low dose of MSCs,
they achieved similar therapeutic effects as a high dose of
free MSCs for up to 8 wk post-injection by macroscopic,
histological, and radiographic analyses. This was the first
evidence where microscopic porous hydrogels were able to
deliver highly efficient injectable MSC therapy using a small
dose of cells in an OA animal model. A similar method may
be useful for improving the treatment efficacy of intra-




Three-dimensional gelatin-based microcryogels were seeded
with hUC-MSCs and cultured for 3 d in vitro, before intra-
articular injection into the knee joint in a rat model of OA.
Cartilage degeneration was evaluated at 4 and 8 wk post-
injection (Fig. 1).
Seeding of hUC-MSCs in Microcryogels
hUC-MSCs (EUBIO Technologies) at passage 4 were
cultured in MSC growth medium (BioWit Technologies,
Shenzhen, China), as previously described21. The micro-
cryogels were packed and supplied as 5-mm-diameter discs
(TableTrixTM, CytoNiche Biotech, China)13. The hUC-
MSCs were seeded in a 200-ml cell suspension (2.5  106
cells/ml) onto 20 mg microcryogel discs in a 40-mm-
diameter cell culture dish. Upon contact with aqueous
solution, the microcryogel disc immediately hydrated and
dispersed into 1  105 microcryogels. The seeded micro-
cryogels were incubated at 37C in a humidified chamber
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for 2 h to allow cell adhesion22, following which MSC
growth medium was added.
Morphological Observation of Microcryogels
The morphology of microcryogels dispersed using
phosphate-buffered saline (PBS) was observed using scan-
ning electron microscopy (SEM; FEI Quanta 200). Samples
were fixed using 10% neutral buffered formalin, dehydrated
using graded ethanol, subjected to critical point drying, and
sputter coated with gold for 90 s prior to SEM observation.
Flow Cytometry
Following 0, 3, and 5 d of culture in microcryogels, the hUC-
MSCs were digested from the microcryogels and suspended
in PBS. The anti-human antibodies CD34 (catalog number:
343513), CD44 (catalog number: 338809), CD73 (catalog
number: 344003), CD90 (catalog number: 328113), and
CD105 (catalog number: 323203) (BioLegend, San Diego,
CA, USA) were used for flow cytometry according to the
manufacturer’s instructions. Antibody incubations were con-
ducted on ice for 30 min. The hUC-MSCs were then washed
and resuspended in PBS for analysis by flow cytometry (BD
LSRFortessa SORP, USA).
Trilineage Differentiation Assay
For all differentiation assays, hUC-MSCs were first cultured
in microcryogels for 0, 3, and 5 d before being digested, and
were subsequently seeded in six-well plates. Cells were cul-
tured in growth medium for 12 h followed by changing to
differentiation medium. The trilineage differentiation ability
of hUC-MSCs was assessed by culturing the cells in
StemPro® differentiation media (Gibco, Life Technologies,
USA) to induce osteogenesis, chondrogenesis, and adipo-
genesis. Osteogenesis was assessed at 14 d by staining the
cells for alkaline phosphatase with the BCIP/NBT Kit
(Sigma-Aldrich, USA) according to the manufacturer’s
instructions. Chondrogenesis was assessed at 14 d by stain-
ing for sulfated proteoglycan deposits with Alcian-Blue
Staining Solution (Sigma-Aldrich). Adipogenesis was
assessed at 21 d by staining for lipid accumulation with an
Oil Red O Kit (Sigma-Aldrich).
Cell Proliferation
Cell proliferation was assessed at 0, 3, and 5 d of culturing
hUC-MSCs in microcryogels, by calculating the number of
cells per 20 mg of microcryogels in microscope. The viabi-
lity of hUC-MSCs within the microcryogels was visualized
using live/dead staining (Life Technologies).
Intra-articular Injection in an OA Animal Model
The animal experiment was performed with approval from
the Peking University Biomedical Ethics Committee. Thirty
Sprague Dawley rats (10 wk old; weighing 180 + 47 g) were
randomly divided into four groups: control (n¼ 6), low-dose
free MSCs (n¼ 8), high-dose free MSCs (n¼ 8), and micro-
cryogelsþMSCs (n¼ 8). Bilateral knee OA was induced by
anterior cruciate ligament (ACL) transection. Briefly, the
rats were anesthetized and surgery was performed to transect
the ACL to induce destabilization of the knee joint. After
surgery, each rat was administered penicillin once a day for
the first 3 d. Rats were treated with intra-articular injection in
both knees at 4 wk after ACL surgery. The control group was
injected with 100 ml saline. For the low-dose and high-dose
free MSC groups, hUC-MSCs were injected at 1 105 and 1
 106 cells/knee, respectively, in 100 ml saline. For the
microcryogels þMSCs group, 1  105 hUC-MSCs in about
0.5 to 0.7 mg microcryogels in saline with a total volume of
100 ml were injected. Cartilage degeneration was evaluated
at 4 and 8 wk after treatment by macroscopic examination,
micro-computed tomography (m-CT), and histology.
Figure 1. Schematic illustration of the study design. hUC-MSCs were seeded in 3D microcryogels and cultured for 3 d before intra-articular
injection into the knee joint in a rat model of OA.
3D: three-dimensional; hUC-MSC: human umbilical cord-derived mesenchymal stem cell; OA: osteoarthritis.
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m-CT Analysis. After sacrificing the rats at 4 and 8 wk after
treatment, intact knee samples were imaged using a m-CT
system (Inveon MM CT, Siemens AG, Munich, Germany).
A scanning time of 0.21 s with settings of 80 kVp, 500 mA,
and 30 calibrations was used. Axial and transaxial fields of
view of 30 mm were acquired. 3D reconstructions were gen-
erated from 2D images using multimodal 3D visualization
software (Inveon Research Workplace, Siemens). For the
medial femoral condyle, the region of interest was acquired
from subchondral bone. An appropriate threshold was
adjusted to define the mineralized bone phase. Bone mineral
density (bone volume/total volume) was calculated three
times for each sample. A semi-quantitative method based on
the degree of osteophyte formation and joint destruction was
used to grade the degree of OA changes in the joint23,24.
Macroscopic Evaluation. Following m-CT analysis, the surface
of the distal femur of each knee joint was exposed. Macro-
scopic evaluation was conducted according to the cartilage
repair assessment instrument of the International Cartilage
Repair Society (ICRS)25. The assessment was performed
based on macroscopic examination of the cartilage surface,
which was scored from 4 to 0 (4: Intact smooth surface, 3:
Fibrillated surface, 2: Small, scattered fissures or cracks, 1:
Figure 2. Characteristics of microcryogels. (A) Packed microcryogels in a tablet form. (B) Morphology of microcryogels dispersed in
phosphate-buffered saline. (C) Microscopic observation of microcryogels. (D, E) Images of microcryogels. (F) SEM images of microcryogels
seeded with mesenchymal stem cells.
SEM: Scanning electron microscopy.
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Several, small or few but large fissures, 0: Total degenera-
tion of surface area).
Histology and Immunohistochemistry. Following macroscopic
examination, the knee joints were fixed in 4% paraformal-
dehyde overnight. Decalcification was conducted in 4%
ethylenediamine tetraacetic acid for 1 mo, with the decalci-
fying solution changed every 3 d. Decalcified joints were
embedded in paraffin and 4 mm sections of the medial
femoral condyle were cut. The sections were stained using
hematoxylin and eosin (HE), safranin-O, and toluidine blue.
The severity of cartilage degeneration was assessed using
the Mankin score26 based on histological findings, namely
(1) structure (score 0 to 6), (2) cells (score 0 to 3), (3)
safranin-O staining (score 0 to 4), and (4) tidemark integrity
(score 0 to 1). A higher score indicated a greater level of
cartilage degeneration.
Immunohistochemical staining was conducted using the
histological sections. Briefly, after deparaffinization, sec-
tions were incubated with 0.3% hydrogen peroxide for
30 min and treated with hyaluronidase for 60 min. The
sections were then incubated with COL-I or COL-II
monoclonal antibodies (Santa Cruz Biotechnology, USA).
All antibody dilutions were made in PBS. After an over-
night reaction with the primary antibody at 4C, sections
were incubated with labeled polymer-horseradish peroxi-
dase anti-mouse immunoglobulin G at room temperature
for 30 min.
Statistical Analysis
All data were expressed as mean + standard deviation. After
testing for homogeneity of variances, one-way analysis of
variance followed by Tukey’s post hoc multiple comparisons
test were used to determine significant differences between
Figure 3. Characterization of hUC-MSCs cultured in microcryogels. (A) Schematic illustration of the timeline for in vitro culture of hUC-
MSCs in microcryogels. (B) Fluorescence microscopy images of MSCs with live/dead staining and (C) number of MSCs in microcryogels over
5 d. (D) Trilineage differentiation ability and (E) surface marker expression by flow cytometry of MSCs following 0, 3, and 5 d of culture in
microcryogels.
3D: three-dimensional; hUC-MSC: human umbilical cord-derived mesenchymal stem cell.
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groups. SPSS 11.0 was used to perform statistical analyses,




The gelain-based 3D microcryogels were packed into a
tablet form for storage (Fig. 2A). Upon contact with PBS
(or any other liquid), the tablets dispersed into loose micro-
cryogels (Fig. 2B). Observations using a light microscope
showed that the microcryogels had a round, translucent,
and uniform appearance (Fig. 2C). SEM images of micro-
cryogels showed their interconnected and macroporous
structure (Fig. 2D, E), which would greatly facilitate cell
loading.
Characterization of hUC-MSCs Cultured in
Microcryogels
hUC-MSCs were seeded in microcryogels and cultured over
5 d for in vitro analyses (Fig. 3A). Live/dead staining
showed that the vast majority of cells were alive at 0, 3, and
5 d of culture in microcryogels (Fig. 3B). The number of
cells in one tablet worth of microcryogels increased signif-
icantly from 0 to 3 d, but remained relatively stable between
3 and 5 d (Fig. 3C).
hUC-MSCs cultured for 0, 3, and 5 d in microcryogels
and subsequently digested for trilineage differentiation test-
ing showed the ability to undergo osteogenesis, chondrogen-
esis, and adipogenesis through differentiation-specific
staining assays (Fig. 3D). At 0, 3, and 5 d, the cells also
showed positive staining for the MSC-specific surface mar-
kers CD44, CD73, CD90, and CD105, as well as negative
staining for CD45 and CD34 (Fig. 3E).
Figure 4. Macroscopic evaluation. (A) Schematic of the in vivo study timeline. (B) Surgical procedure for anterior cruciate ligament
transection to establish the rat osteoarthritis model. The skin and fascia on the knee cap region of the hind limb were vertically incised
in the midline for a distance of approximately 4 cm. The patella was retracted laterally to expose the articular cavity. The anterior cruciate
ligaments were transected. The patella was relocated back to its original position, and the fascia and skin were closed with sutures. (C)
Representative macroscopic images of the femoral condyle in different groups at 4 and 8 wk after injection. (D) ICRS macroscopic scores of
the femoral condyle at 4 and 8 wk after injection. ****P < 0.0001.
ICRS: International Cartilage Repair Society; MSC: mesenchymal stem cell.
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Since hUC-MSCs grown in microcryogels for 3 d gave
rise to peak cell numbers and viability, as well as main-
tenance of their MSC phenotype, microcryogels contain-
ing hUC-MSCs precultured for 3 d were used as the
microcryogels þ MSCs group for subsequent in vivo
testing.
In Vivo Effects of Microcryogels Containing hUC-MSCs
in an OA Model
Macroscopic Evaluation. The effects of treatments by intra-
articular injection in a rat OA model were evaluated at 4 and
8 wk after injection (Fig. 4A). OA was induced in the rat
model by ACL transection (Fig. 4B). Macroscopic examina-
tion of the joint surface of the distal femur at 4 wk showed
that the control and low-dose free MSC groups had marked
signs of OA progression, including cartilage surface rough-
ness and osteophyte formation (Fig. 4C). In contrast, the
high-dose free MSCs and microcryogels þ MSC groups
showed a well-preserved cartilage surface. At 8 wk, more
severe OA progression had occurred in the control and low-
dose free MSC groups, which showed a highly disrupted
cartilage surface. In the high-dose free MSCs and microcryo-
gels þ MSC groups, the cartilage surface was smooth and
had a relatively normal appearance. Accordingly, the ICRS
macroscopic scores for the high-dose free MSCs and micro-
cryogels þ MSC groups were significantly higher than the
other two groups at both 4 and 8 wk (Fig. 4D). There were no
significant differences between ICRS scores of the high-dose
free MSCs and microcryogels þ MSC groups at either time
point.
m-CT Analysis. Representative m-CT images of knee samples
at 4 and 8 wk post-treatment showed radiological osteophyte
formation around the knee joint in all groups (Fig. 5A).
However, a greater number of samples in the high-dose free
MSCs and microcryogels þ MSC groups showed lower
grades of OA change than the control and low-dose free
MSC groups by m-CT analysis (Fig. 5B). The groups showed
no significant differences in bone mineral density (BV/TV)
at 4 and 8 wk (Fig. 5C).
Histological and Immunohistochemical Analyses. Representative
histological images of the medial femoral condyle are shown
for all groups stained using HE, safranin-O, and toluidine
blue at 4 and 8 wk (Fig. 6A). At 4 wk, the articular cartilage
in the control and low-dose free MSC groups showed surface
irregularity, loss of cellularity, and reduced area of safranin-
O staining, indicating significant OA changes. In contrast,
the high-dose free MSCs and microcryogels þ MSC groups
showed abundant proteoglycan in the articular cartilage and
reduced cartilage loss, without significant features of OA
progression. The same joint structure was preserved at 8
wk. On the other hand, knee joints in the control and low-
dose free MSC groups showed increased OA progression at
8 wk, with significant loss of joint integrity and proteoglycan
content. Accordingly, the high-dose free MSCs and micro-
cryogels þ MSC groups showed similar Mankin scores at 4
and 8 wk, which were significantly higher than the other two
Figure 5. m-CT analysis. (A) Posterior-anterior views of the knee
joint in all groups by m-CT at 4 and 8 wk after injection. (B) The
grade of OA change for individual samples in all groups at 4 and 8
wk. (C) Bone mineral density (BV/TV) of subchondral bone in the
medial femoral condyle at 4 and 8 wk.
m-CT: micro-computed tomography; MSC: mesenchymal stem cell;
OA: osteoarthritis; BV: bone volume; TV: total volume.
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groups (Fig. 6B). Immunohistochemical staining showed
that collagen types I and II were both more abundant in
the high-dose free MSCs and microcryogels þ MSC
groups compared to the other two groups at 4 and 8 wk
(Fig. 6C).
Discussion
Over the last decade, cell therapy using MSCs has been
increasingly explored as a potential new approach for treat-
ing OA, with some early-phase clinical studies
Figure 6. Histological and immunohistochemical analyses. (A) Histological images of articular cartilage in the medial femoral condyle of all
groups, stained by HE, safranin-O, and toluidine blue, and (B) Mankin scores at 4 and 8 wk after injection. (C) Immunohistochemical staining
for collagen types I and II at 4 and 8 wk. ****P < 0.0001.
HE: hematoxylin and eosin; MSC: mesenchymal stem cell.
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demonstrating promising outcomes27–29. However, our
recent reviews on the current evidence of using intra-
articular injections of MSCs to treat knee OA in animal
studies and clinical trials showed inconclusive benefits, and
indicated low confidence of recommending this as a reliable
long-term therapy for OA8,30. Our recent study in a rat model
of OA also revealed that a single injection of MSCs can only
have temporary, early-stage effects on the progression of
cartilage degeneration rather than prolonged effectiveness
in disease modification13.
The lack of long-term effects of MSC therapy in OA and
other pathologies may be due to poor retention, survival, and
function of the transplanted cells31,32. To circumvent these
problems and increase the efficacy of cell therapy for OA,
simply increasing the cell dose or increased number of injec-
tions may be an option. In this study, we confirmed that a
high dose of 1 106 free MSCs produced significantly better
therapeutic effects than a low dose of 1  105 cells in a rat
OA model. Another study in a small cohort of patients also
found that a single intra-articular injection of 100 compared
to 10 million MSCs was more effective in attenuating joint
damage in knee OA15. However, this approach may not be
economically viable for large-scale clinical use due to the
limited sources of MSCs and the costs of cell harvesting and
expansion33,34. Although various peptides and antibodies
can be used to direct cells to targeted repair sites35,36, which
can improve cell retention and potentially reduce the
required cell dose, these approaches are associated with
immune reactions and safety concerns. In this study, we used
a new approach comprising injectable microcryogels as
MSC carriers, which not only can enhance cell survival and
retention following injection into the OA joint, but also
improve cell function by allowing native cell–cell interac-
tions and ECM deposition within the carrier14,20,21. We
showed that the microcryogels loaded with a low dose of
MSCs achieved similar therapeutic effects as a high dose of
MSCs in a rat model of knee OA.
The microcryogels we previously developed could be
aggregated into a tablet form for long-term preservation,
enabling their use as an off-the-shelf product. These micro-
cryogels were fabricated by cryogelation of gelatin, and once
dispersed in aqueous solution can maintain their highly por-
ous and interconnected structure, which facilitates efficient
cell loading by automatic absorption20. In this study, the
hUC-MSCs were easily loaded into the microcryogels by
simply pipetting the cell suspension onto the surface of the
microcryogel tablet. We considered the timing for preculture
of MSCs in microcryogels as a critical parameter for optimal
therapeutic efficacy, as long-term culture could lead to
senescence, which ultimately reduces cell quality37. We
chose 3 d as the duration for in vitro preculture of MSCs
in microcryogels prior to in vivo injection, as this time period
allowed peak MSC viability and proliferation, as well as
stable maintenance of phenotypic characteristics, all of
which were suggestive of an optimal balance between cell
function and ECM accumulation (eventually leading to cell
senescence).
The cell number for intra-articular injection in low-dose
free MSCs and microcryogels þ MSCs was 1  105.
Although priming MSCs in microcryogels led to the prolif-
eration of MSCs, we confirmed that the cell number for
injection was 1  105 in total 10 ml saline. By MSCs’ diges-
tion from the microcryogels, we estimated about 1/30 20 mg
microcryogels including 1 105 MSCs. Thus, 20 mg micro-
cryogels with MSCs that were primed for 3 d was dispersed
in 3 ml saline before injection. At 4 and 8 wk after in vivo
injection, joints injected with high-dose free MSCs and
microcryogels þMSCs showed similar histological features
characterized by relatively normal articular cartilage struc-
ture and cell distribution, appropriate thickness, consistent
safranin-O staining, and only mild irregularities in the sur-
face layer. In contrast, joints injected with the control and
low-dose free MSCs showed structural disorganization in the
cartilage and significant OA progression. These results were
consistent with the macroscopic and radiological findings,
which collectively suggested that by using the microcryogels
as cell carriers, a low dose of MSCs can exert similar treat-
ment effects as a high dose of free MSCs in protecting joint
cartilage from degradation during OA progression. More-
over, the protective effects were evident over a relatively
long period of 8 wk, and no adverse effects were observed
in the microcryogels þMSCs group throughout the duration
of the study.
The therapeutic efficacy seen in the microcryogels þ
MSCs group is likely due to the microcryogels creating a
microenvironment for the MSCs that maximizes their para-
crine functions. The beneficial properties of MSCs in treat-
ing OA are thought to be linked to their release of
immunomodulatory factors and chemoattractants, which
exert an indirect effect by enriching the repair environ-
ment38. Subjecting the MSCs to a microenvironment that
promotes natural ECM accumulation can contribute to mod-
ulating cell behavior and fate, as the biophysical and bio-
chemical cues generated during ECM formation can activate
distinct signaling pathways and enhance cell function39,40.
The microcryogels can provide the MSCs with such a micro-
environment and facilitate natural cell–cell and cell–ECM
interactions, which can increase their paracrine secretions
and result in a range of effects that are beneficial for cartilage
repair, including cell homing, anti-inflammation, and
immune regulation41–43. Moreover, the microcryogels con-
taining accumulated ECM may better preserve the MSC-
secreted exosomes to help suppress OA development44,45.
The microcryogels may also offer physical protection to the
MSCs by shielding them from mechanical insult and necro-
sis during and after cell injection14,46,47.
Collectively, the results of this study suggested that MSC-
laden microcryogels were a safe and effective approach for
achieving therapeutic efficacy in a small animal model of
OA while minimizing the required cell dose. The outcomes
of using MSC-laden microcryogels with different sources of
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MSCs and initial cell doses, and testing in larger animal
models of OA will be explored in future studies.
Conclusion
Intra-articular injection of 3D microcryogels loaded with a
low dose of hUC-MSCs (1  105 cells) had similar thera-
peutic effects as a high dose of free hUC-MSCs (1  106),
which decelerated the progression of cartilage destruction in
a rat OA model. This MSC delivery strategy using micro-
cryogels may hold potential as a superior cell therapy
approach for OA that reduces cost and limits the risk of side
effects by minimizing the required cell dose to achieve ther-
apeutic efficacy.
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